Misplaced Pages

Pateclizumab: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 14:19, 26 September 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,416 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper← Previous edit Latest revision as of 23:37, 3 December 2023 edit undoCitation bot (talk | contribs)Bots5,460,228 edits Add: doi-access. | Use this bot. Report bugs. | #UCB_CommandLine 
Line 48: Line 48:
}} }}


'''Pateclizumab''' ('''MLTA3698A''') is an immunomodulator. It binds to ].<ref>{{cite journal | author = ] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf }}{{dead link|date=December 2021|bot=medic}}{{cbignore|bot=medic}}</ref><ref>, '']''.</ref><ref>{{cite journal |vauthors=Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC |title=Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |journal=Arthritis Res. Ther. |volume=16 |issue=5 |pages=467 |date=October 2014 |pmid=25359150 |pmc=4243296 |doi=10.1186/s13075-014-0467-3 }}</ref><ref>{{cite journal |vauthors=Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC |title=Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial |journal=Arthritis Res. Ther. |volume=14 |issue=1 |pages=R6 |date=January 2012 |pmid=22225620 |pmc=3392792 |doi=10.1186/ar3554 }}</ref><ref>{{cite journal |vauthors=Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G |title=Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates |journal=Reprod. Toxicol. |volume=63 |pages=82–95 |date=August 2016 |pmid=27211603 |doi=10.1016/j.reprotox.2016.05.014 |s2cid=41454952 }}</ref><ref>{{cite journal |vauthors=Hirose T, Fukuma Y, Takeshita A, Nishida K |title=The role of lymphotoxin-α in rheumatoid arthritis |journal=Inflamm. Res. |volume=67 |issue=6 |pages=495–501 |date=June 2018 |pmid=29541795 |doi=10.1007/s00011-018-1139-6 |s2cid=3910200 }}</ref> '''Pateclizumab''' ('''MLTA3698A''') is an immunomodulator. It binds to ].<ref>{{cite journal | author = ] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf }}{{dead link|date=December 2021|bot=medic}}{{cbignore|bot=medic}}</ref><ref>, '']''.</ref><ref>{{cite journal |vauthors=Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC |title=Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |journal=Arthritis Res. Ther. |volume=16 |issue=5 |pages=467 |date=October 2014 |pmid=25359150 |pmc=4243296 |doi=10.1186/s13075-014-0467-3 |doi-access=free }}</ref><ref>{{cite journal |vauthors=Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC |title=Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial |journal=Arthritis Res. Ther. |volume=14 |issue=1 |pages=R6 |date=January 2012 |pmid=22225620 |pmc=3392792 |doi=10.1186/ar3554 |doi-access=free }}</ref><ref>{{cite journal |vauthors=Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G |title=Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates |journal=Reprod. Toxicol. |volume=63 |pages=82–95 |date=August 2016 |pmid=27211603 |doi=10.1016/j.reprotox.2016.05.014 |s2cid=41454952 }}</ref><ref>{{cite journal |vauthors=Hirose T, Fukuma Y, Takeshita A, Nishida K |title=The role of lymphotoxin-α in rheumatoid arthritis |journal=Inflamm. Res. |volume=67 |issue=6 |pages=495–501 |date=June 2018 |pmid=29541795 |doi=10.1007/s00011-018-1139-6 |s2cid=3910200 }}</ref>


This drug was developed by ]/]. This drug was developed by ]/].

Latest revision as of 23:37, 3 December 2023

Monoclonal antibody Pharmaceutical compound
Pateclizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetlymphotoxin alpha
Clinical data
Other namesMLTA3698A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6436H9910N1710O2004S44
Molar mass144716.68 g·mol
  (what is this?)  (verify)

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.

This drug was developed by Genentech/Roche.

References

  1. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
  3. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014). "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)". Arthritis Res. Ther. 16 (5): 467. doi:10.1186/s13075-014-0467-3. PMC 4243296. PMID 25359150.
  4. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012). "Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial". Arthritis Res. Ther. 14 (1): R6. doi:10.1186/ar3554. PMC 3392792. PMID 22225620.
  5. Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol. 63: 82–95. doi:10.1016/j.reprotox.2016.05.014. PMID 27211603. S2CID 41454952.
  6. Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res. 67 (6): 495–501. doi:10.1007/s00011-018-1139-6. PMID 29541795. S2CID 3910200.


Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse
Chemokine receptor modulators
CC
CCR1
CCR2
CCR3
CCR4
CCR5
CCR6
CCR7
CCR8
CCR9
CCR10
CCR11
Ungrouped
CXC
CXCR1
(IL-8Rα)
CXCR2
(IL-8Rβ)
CXCR3
CXCR4
CXCR5
CXCR6
CXCR7
C (XC)
XCR1
CX3C
CX3CR1
Others
CCBP2
CMKLR1


Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Pateclizumab: Difference between revisions Add topic